Urothelial Carcinoma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Any male or female patient aged 18 or older.; 2. Understand the purpose of the clinical trial and sign the informed consent; 3. Meet one of the following conditions: (1) Patients with urothelial carcinoma or benign diseases of the urinary system or other malignant tumors of the urinary system other than urothelial carcinoma with symptoms of hematuria (intermittent, painless whole-course gross hematuria and microscopic hematuria) and/or bladder irritation (frequent, urgent and painful urination); (2) Patients with non-urinary malignancy; (3) Volunteers without symptoms of urinary system diseases (no obvious abnormalities in routine uronoscopy and Type B ultrasonic). 4. The above-mentioned urothelial carcinoma, benign diseases of the urinary system, other malignancies of the urinary system, non-urinary malignancies and volunteers without symptoms of urinary system diseases had no complicated other malignancies, and no history of other malignancies; 5. Urine samples from patients with malignant tumors should be collected according to tumor load state and preoperative (including radical resection, partial resection, endoscopic surgery or biopsy, etc.), and the samples collected should meet the requirements of the program samples; 6. Enrolled patients should be outpatients or inpatients with pathological diagnosis and/or clinical diagnosis and with complete case information.
Exclusion criteria
Exclusion criteria: 1. The sample does not meet the requirements of the research plan; 2. Incomplete pathological diagnosis and clinical diagnosis information or no definite diagnosis results can be obtained; 3. The situation that other researchers consider unsuitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DNA methylation; | — |
Countries
China
Contacts
Sun Yat-sen Memorial Hospital, Sun Yat-sen University